MANANDHAR, N. R.; KAYASHTA, G. K.; ACHARYA, P. K. Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study. Journal of Patan Academy of Health Sciences, [S. l.], v. 5, n. 1, p. 47–56, 2018. DOI: 10.3126/jpahs.v5i1.24042. Disponível em: https://www.nepjol.info/index.php/JPAHS/article/view/24042. Acesso em: 29 mar. 2024.